By: Eric Cheng, PhD
World health leaders agree on action to combat antimicrobial resistance, warning of nearly 10 million deaths annually if left unchecked
World leaders committed to take action on antimicrobial resistance during their September 21, 2016 high-level meeting on Antimicrobial Resistance in New York. This is the first time Heads of State made a commitment to address the root cause of antimicrobial resistance in human health, animal health, and agriculture. Dr. Margaret Chan, Director-General of the World Health Organization emphasized that “antimicrobial resistance poses a fundamental threat to human health, development, and security. The commitments made today must now be translated into swift, effective, lifesaving actions across the human, animal and environmental health sectors. We are running out of time.”
The committed countries pledged to strengthen regulation of antimicrobials, improve knowledge and awareness, and promote best practices. World leaders also agreed to foster innovative approaches using alternatives to antimicrobials and new technologies for diagnosis and vaccines. The committed countries will base their national action plans on the Global Action Plan on Microbial Resistance, a blueprint developed in 2015 by the World Health Organization along with Food and Agriculture Organization of the United Nations and the World Organization for Animal Health. (United Nations Meetings Coverage and Press Releases)
Documents reveal intense battle over CDC Zika tests
In addition to battling the spread of Zika infections, the Center for Disease and Prevention (CDC) is currently in an internal battle with determining which test will be best in diagnosing someone with the disease. Robert Lanciotti is the Chief of the Diagnostics and Reference Activity in the Division of Vector-Borne Infectious Diseases in Fort Collins, CO. At the center of the debate is the agency’s prioritization of the Trioplex real-time PCR-based assay that tests for Zika, dengue, and chikungunya over the Singleplex assay which only detects Zika, which Lanciotti’s research found to be 39% more effective than the Trioplex assay.
Lanciotti claimed that the CDC “created a substantial and specific danger to public health” when it did not disclose lower sensitivity of the test it used. Lanciotti was subsequently reassigned to a non-supervisory position in his laboratory who then filed a whistleblower retaliation claim with the US Office of Special Counsel. Lanciotti alleged that the demotion was because of his concerns with the Zika test. Lanciotti has since been reinstated as director of his lab. In addition, the Office of Special Counsel requested that the CDC investigate Lanciotti’s concerns with the sensitivity of the Trioplex test.
The CDC’s own investigation found that Dr. Lanciotti’s allegations “are not substantiated by the available evidence.” The CDC ruled that “[t]here is insufficient, statistically robust, definitive data to reach an evidence-based conclusion that use of the Trioplex assay over the Singleplex in clinical practice will result in 39 percent of Zika virus infections being missed.” The CDC also noted that it is continuing to improve on the Trioplex assay such as enabling testing laboratories to use larger sample volumes in order to increase the assay’s limit of detection. The Trioplex assay is still approved for use as a method of detecting Zika virus, dengue, and chikungunya. (Jon Cohen, Science Magazine)
HHMI Launches New Program for Early-Career Scientists
The Howard Hughes Medical Institute (HHMI) recently launched a new program to recruit and retain early-career scientists that are underrepresented in the life sciences. These individuals include those coming from a disadvantaged background. The selected HHMI scientists will become Hanna H. Gray fellows, named after Hanna H. Gray, former chair of the HHMI Trustees and former president of the University of Chicago.
The purpose of the Gray Fellows Program is to find and encourage talented students and early scientists that are committed to continuing their scientific training in the nation’s top laboratories. The Hanna H. Gray Fellows grant competition is open to all eligible applicants and no nomination is required. Selected fellows are required to devote at least 75 percent of their total effort to research during both the postdoctoral training and faculty phases of the award. In addition, part of the goal for the program is to position Gray fellows to be competitive for NIH grants and other awards when they transition to the faculty phase of their careers. (Howard Hughes Medical Institute)
Have an interesting science policy link? Share it in the comments!